SS-31 (Elamipretide): The Mitochondria-Targeting Peptide Research Guide

What Is SS-31 (Elamipretide)?

SS-31, also known by its developmental name Elamipretide and the research identifier MTP-131, is a synthetic tetrapeptide with the amino acid sequence D-Arg-2′6′-Dmt-Lys-Phe-NH₂. It was developed at Cornell University by researchers Hazel Szeto and Peter Schiller — the "SS" in its name stands for Szeto-Schiller — and belongs to a novel class of compounds called Szeto-Schiller (SS) peptides, designed specifically to concentrate in the inner mitochondrial membrane.

Unlike most peptides that circulate in the bloodstream or bind surface receptors, SS-31 is engineered to selectively accumulate within mitochondria at a roughly 1,000-fold concentration relative to the cytoplasm. This mitochondrial targeting is its defining pharmacological property, and it distinguishes SS-31 from virtually all other compounds in the peptide research space.

Research interest in SS-31 spans mitochondrial biology, cardiac function, renal protection, skeletal muscle physiology, and aging science. Several clinical trials have completed, including multiple Phase II trials in heart failure patients, making it one of the more clinically evaluated research peptides available.

Molecular Profile

Mechanism of Action

SS-31 exerts its effects through a relatively well-characterized mechanism centered on cardiolipin, a unique phospholipid found almost exclusively in the inner mitochondrial membrane.

Cardiolipin binding. Cardiolipin plays a structural role in organizing the electron transport chain (ETC) complexes into supercomplexes — organized clusters of complexes I, III, and IV that dramatically improve electron transfer efficiency. When mitochondria are stressed (aging, ischemia, oxidative damage), cardiolipin becomes oxidized, disrupting supercomplex organization. This causes electrons to "leak" from the ETC and react with oxygen to form superoxide — the primary mitochondrial reactive oxygen species (ROS).

SS-31 binds cardiolipin directly via electrostatic and hydrophobic interactions. Its aromatic residues (2′6′-Dmt and Phe) intercalate into the cardiolipin acyl chains while its positively charged residues (D-Arg and Lys) interact with the negatively charged phosphate headgroups. This binding stabilizes cardiolipin against oxidation and preserves its structural role.

Cytochrome c interaction. Cardiolipin also anchors cytochrome c (Cyt c) to the inner membrane. In stressed mitochondria, oxidized cardiolipin releases Cyt c, which can trigger apoptosis. SS-31 stabilizes this interaction, keeping Cyt c associated with the membrane and functioning in electron transfer rather than leaking into the cytoplasm.

Net effects documented in preclinical research:

• Reduced mitochondrial ROS production
• Improved ATP synthesis efficiency (higher ATP-to-oxygen ratio)
• Restored ETC supercomplex formation
• Reduced opening of the mitochondrial permeability transition pore (mPTP)
• Attenuated apoptosis signaling downstream of mitochondrial stress

These mechanisms make SS-31 relevant to any condition where mitochondrial dysfunction is a contributing factor — which increasingly includes aging itself, as mitochondrial integrity declines with age across most tissue types.

What the Research Actually Shows

Cardiac Function

The most extensive human data for SS-31 comes from cardiac research. The STRIVE-HF trial and related studies enrolled patients with heart failure with preserved ejection fraction (HFpEF) — a form of heart failure where the heart muscle stiffens and relaxes poorly rather than failing to pump adequately.

A Phase II trial published in JACC: Basic to Translational Science (Daubert et al., 2017) administered IV elamipretide to HFpEF patients and found statistically significant improvements in six-minute walk distance and quality-of-life scores at four weeks, along with favorable trends in echocardiographic parameters of diastolic function. The effect size was modest but considered clinically meaningful for this patient population, which has limited treatment options.

A Phase II trial in mitral regurgitation patients (the EVOLVE-HF trial) demonstrated that IV elamipretide for five days prior to surgical repair improved left ventricular remodeling markers compared to placebo. Patients receiving elamipretide showed better preservation of left ventricular end-systolic volume index at six months.

Preclinical cardiac data is extensive. In aged dogs with naturally occurring heart failure, subcutaneous SS-31 administration for three months improved mitochondrial morphology, restored ETC complex activity, and significantly improved cardiac output — findings published by Sabbah et al. across multiple papers in Circulation: Heart Failure and Journal of Cardiac Failure. This aged-dog model is considered more translatable than rodent models due to its spontaneous disease onset.

Important caveat: Most human trials have used IV infusion protocols under clinical supervision, not subcutaneous self-administration protocols. The clinical trials use pharmaceutical-grade elamipretide formulated for injection, which differs from research peptide preparations.

Renal Protection

Acute kidney injury (AKI) and chronic kidney disease (CKD) both involve significant mitochondrial dysfunction in renal tubular cells. SS-31 has been studied in this context in both animal models and one human clinical trial.

In a randomized controlled trial published in Journal of the American Society of Nephrology (JASN) by Birk et al. (2013), IV SS-31 administered to patients with CKD undergoing elective cardiac catheterization significantly reduced contrast-induced AKI incidence (from ~39% in placebo to ~9% in the SS-31 group), as measured by serum creatinine rise over 48 hours. This is a single relatively small trial (n=36 evaluable) and requires replication, but the result was statistically significant and mechanistically plausible.

Rodent and non-human primate studies show SS-31 protects against ischemia-reperfusion kidney injury, cisplatin nephrotoxicity, and diabetic nephropathy progression. The renal tubular cells are among the most mitochondria-dense cells in the body, which makes the kidney a logical target organ for SS-31's mechanism.

Skeletal Muscle and Physical Function

Muscle mitochondria decline in density and function with aging — a major contributor to sarcopenia and reduced physical capacity in older adults. SS-31 has been studied in this context through both animal models and one human trial.

A Phase II trial by Bhaskaran et al. (2020) administered subcutaneous SS-31 daily for four weeks to older adults (70+) with mitochondrial dysfunction confirmed by muscle biopsy. The trial found significant improvements in gait speed and self-reported physical function scores versus placebo, along with measurable improvements in mitochondrial function assessed by phosphorus MR spectroscopy (a non-invasive measure of mitochondrial ATP production). The sample was small (n=25), but the biological endpoints added mechanistic credibility beyond self-reported outcomes.

In aged rodent models, SS-31 reliably restores mitochondrial structure in skeletal muscle, reduces intramyocellular lipid accumulation, and improves both endurance and strength metrics. The consistency across aging models is notable.

Aging Biology

SS-31 is of particular interest in geroscience because mitochondrial dysfunction is considered a primary "hallmark of aging" (López-Otín et al., Cell, 2023 updated framework). Several labs have investigated whether SS-31 can reverse age-associated mitochondrial decline.

Studies in aged mice show that SS-31 treatment restores mitochondrial ultrastructure (cristae morphology) in multiple tissues, improves physical performance on rotarod and grip-strength tests, and reduces tissue levels of oxidative damage markers. No lifespan extension data exists for SS-31 in mice, which distinguishes it from compounds like rapamycin with formal ITP-tested lifespan data.

Importantly, SS-31 appears to act on the mitochondria as they exist rather than increasing mitochondrial biogenesis (which is PGC-1α-mediated). It is sometimes described as a "mitochondrial resuscitator" rather than a biogenesis stimulator — restoring existing mitochondrial function rather than making new ones.

Comparison to Related Mitochondria-Targeting Compounds

SS-31 is unique in directly targeting cardiolipin and modulating ETC supercomplex architecture. MitoQ and SkQ1 are antioxidants delivered to mitochondria; urolithin A clears dysfunctional mitochondria; CoQ10 supports electron transfer non-selectively. The mechanisms are complementary rather than redundant.

Research Limitations

Administration route mismatch. Human trials have used IV infusion, not subcutaneous injection. Whether subcutaneous administration in research settings produces equivalent tissue concentrations is unknown from published data.

Small trial sizes. Most human trials have had 20–50 participants. Effect estimates carry wide confidence intervals.

Short observation windows. Most trials ran 4–12 weeks. Long-term efficacy and safety data are not available.

Bioavailability variability. As a tetrapeptide, SS-31 is susceptible to peptidase degradation. Plasma half-life is short, and tissue concentrations depend heavily on injection site, formulation, and individual differences in peptide metabolism.

No lifespan data. Unlike rapamycin, SS-31 has not been tested in formal lifespan extension studies (e.g., the NIA Interventions Testing Program).

Regulatory status. Elamipretide is an investigational new drug (IND) in the United States. It has not received FDA approval for any indication, though it has received FDA Breakthrough Therapy designation for Barth syndrome (a genetic mitochondrial cardiomyopathy).

Peptide source variability. Research peptide preparations vary in purity, enantiomeric composition, and stability. D-amino acid content is critical for SS-31's biological activity, and verification of peptide composition in research-grade material requires analytical testing not routinely performed by consumers.

Key Takeaways

1. SS-31 (Elamipretide) is a mitochondria-targeting tetrapeptide that binds cardiolipin in the inner mitochondrial membrane, stabilizing electron transport chain supercomplexes and reducing mitochondrial ROS production.
2. The most robust human clinical data is in cardiac conditions — particularly HFpEF and mitral regurgitation — where IV elamipretide improved functional and structural endpoints in Phase II trials.
3. A single RCT showed SS-31 reduced contrast-induced AKI in CKD patients; this finding requires replication but is mechanistically coherent.
4. A small human trial found improvements in gait speed and mitochondrial function in older adults after four weeks of subcutaneous SS-31, supporting the "mitochondrial aging" hypothesis.
5. Human trials have used IV or SC pharmaceutical-grade preparations; the applicability of these findings to research peptide products is not directly established.
6. SS-31 does not extend lifespan in animal models, and no formal ITP data exists.
7. Among mitochondria-targeting compounds with human data, SS-31 has a distinct mechanism (cardiolipin binding) that differentiates it from antioxidant-delivery approaches (MitoQ) and mitophagy inducers (Urolithin A).

This article is for informational and research reference purposes only. SS-31 (Elamipretide) is an investigational compound that has not received FDA approval for therapeutic use in the indications discussed above (except Breakthrough Therapy designation for Barth syndrome). Research compounds are for laboratory and preclinical research use only. Nothing in this article constitutes medical advice.